NCT02301039

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 144 (actual)
• Sponsor: Sarcoma Alliance for Research through Collaboration · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.

Detailed description

This is a multi-institutional phase II study of pembrolizumab in patients with advanced sarcomas. This study will have two treatment groups, one group for patients with soft tissue sarcoma and one group for patients with bone sarcoma. Initial enrollment for this study included a total of 86 patients with soft tissue sarcoma and bone sarcomas. In the expansion portion, there will be an additional 30 patients with undifferentiated pleomorphic sarcoma (UPS) and 30 patients with dedifferentiated or other high grade liposarcoma (LPS) enrolled into the study.

Conditions

• Soft Tissue Sarcoma
• Bone Sarcoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab

Timeline

• Start date: 2015-03-01
• Primary completion: 2020-07-01
• Completion: 2020-07-01
• First posted: 2014-11-25
• Last updated: 2020-09-29
• Results posted: 2020-09-29

Locations

12 sites across 1 country: United States